News and Updates

uniQure eyes FDA approval for AMT-130, a breakthrough gene therapy for Huntington’s disease. Learn the latest on this potential genetic treatment.

A major medical milestone as the first human receives a wireless Paradromics BCI, designed to restore communication for those with speech impairments.

A new liver-targeted insulin shows potential to improve Type 1 Diabetes management by reducing hypoglycemia risks. Discover how this therapy mimics nature.

VahatiCor has enrolled the first U.S. patient in the SERRA-I trial, testing the A-FLUX Reducer System® to treat Coronary Microvascular Dysfunction (CMD).

Latin Clinical Trial Center and PhaseWell Research partner to scale clinical trials in Puerto Rico, enhancing patient access to innovative new therapies.

Nanvuranlat enters Phase 3 clinical trials following FDA alignment. Learn about the latest developments in this promising oncology therapeutic candidate.

Edgewise Therapeutics announces positive Phase II results for EDG-7500 in treating hypertrophic cardiomyopathy. See how this breakthrough impacts heart care.

Discover why India’s pharma growth is shifting from price hikes to volume-driven demand and what this means for the future of the healthcare industry.

Explore why the Indian pharmaceutical industry is set for sustained double-digit growth driven by complex generics, PLI schemes, and rising domestic demand.

New Phase II data reveals that adding ligufalimab to azacitidine and venetoclax improves overall survival for AML patients. Learn the latest clinical impact.